(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...
The study was small — just 48 adults — and lasted just over two months, so it’s not the final word. But the results add to evidence that GLP-1 drugs like Ozempic might help with cravings for things ...
Hosted on MSN1d
Ozempic Shows Potential for Alcohol Addiction in TrialWeekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback